Jacobs Levy Equity Management, Inc Cassava Sciences Inc Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 224,658 shares of SAVA stock, worth $620,056. This represents 0.0% of its overall portfolio holdings.
Number of Shares
224,658Holding current value
$620,056% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SAVA
# of Institutions
136Shares Held
15.9MCall Options Held
1.26MPut Options Held
791K-
Black Rock Inc. New York, NY3.22MShares$8.89 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$6.32 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.06MShares$5.69 Million0.01% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny962KShares$2.65 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY565KShares$1.56 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $111M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...